Bassatne A, Khalil AB, Chakhtoura M, et al. - Postmenopausal women with early-stage breast cancer are routinely administered aromatase inhibitors (AIs), which improve breast cancer outcomes but increase the risk of osteoporosis and fractures among these women. With the aim to determine the effect of antiresorptive drugs on AI induced bone loss in postmenopausal women with non-metastatic breast cancer, researchers conducted a systematic review and meta-analysis.

• Four databases yielded 14 RCTs for inclusion: 7 on zoledronic acid, 6 on oral bisphosphonates and 1 on denosumab.

• Findings suggest anti-resorptive therapy as protective against AI induced bone loss.

• Postmenopausal women on AI showed improvement in BMD and markers after receiving anti-resorptive therapy.

• Zoledronic acid might lower vertebral fractures in these women.

• The risk of clinical fractures lowers by 50% in correlation with receiving denosumab.